2023
Animal models of Huntington’s disease and their applicability to novel drug discovery and development
Upadhayay S, Jamwal S, Kumar P. Animal models of Huntington’s disease and their applicability to novel drug discovery and development. Expert Opinion On Drug Discovery 2023, 18: 527-538. PMID: 37042034, DOI: 10.1080/17460441.2023.2201493.Peer-Reviewed Original ResearchConceptsHD animal modelsAnimal modelsHuntington's diseaseNon-motor symptomsProgressive neurodegenerative disorderDrug therapyDisease progressionPreclinical phaseLoss of functionNeurodegenerative disordersClinical phaseDrug discoveryDiseaseNovel drug discoveryHuntingtin geneToxic gainCAG trinucleotide repeatDrugsProgressionHD geneEnormous progression
2017
Animal Models of Huntington’s Disease
Kaur N, Jamwal S, Kaur Gill H, Bansal P. Animal Models of Huntington’s Disease. 2017, 43-57. DOI: 10.1007/978-981-10-5981-0_4.Peer-Reviewed Original Research
2016
Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington’s like symptoms in rats: Possible neurotransmitters modulation
Gill JS, Jamwal S, Kumar P, Deshmukh R. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington’s like symptoms in rats: Possible neurotransmitters modulation. Pharmacological Reports 2016, 69: 306-313. PMID: 28178592, DOI: 10.1016/j.pharep.2016.11.008.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCorpus StriatumDisease Models, AnimalGamma-Aminobutyric AcidGlutamic AcidHuntington DiseaseInterleukin-1betaInterleukin-6Lipid PeroxidationMaleMotor ActivityNeuroprotective AgentsNeurotransmitter AgentsOxidative StressQuinolinic AcidRatsRats, WistarRotarod Performance TestSertralineTumor Necrosis Factor-alphaVenlafaxine HydrochlorideConceptsMotor performanceQuinolinic acidAvailable drugsPro-inflammatory cytokine levelsNumerous neuroprotective propertiesAnti-inflammatory propertiesGrip strength testProgressive neurodegenerative disorderBDNF levelsCytokine levelsSymptomatic reliefNeuroprotective effectsRotarod testMonoamine levelsNeuroprotective propertiesStriatal atrophyNeurobehavioral deficitsNeurotransmitter levelsNeurotransmitter modulationGlutamatergic signalingRat striatumNeurochemical analysisBody weightDay 22Neurochemical levels